This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Aurinia Pharmaceuticals Inc. (AUPH) may be one such company.
What's in the Cards for Repros (RPRX) this Earnings Season?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.
Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?
by Zacks Equity Research
Intrexon Corporation (XON) is expected to report first-quarter 2017 results on May 9.
Implied Volatility Surging for Aurinia Pharmaceuticals(AUPH) Stock Options
by Zacks Equity Research
Implied Volatility Surging for Aurinia Pharmaceuticals(AUPH) Stock makes it lucrative to the option traders.
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
by Anupriya Datta
Investors in Aurinia Pharmaceuticals Inc. (AUPH) need to pay close attention to the stock based on moves in the options market lately.
Aurinia (AUPH) Catches Eye: Stock Moves up 8.5% in Session
by Zacks Equity Research
Aurinia Pharmaceuticals Inc. (AUPH) moved big last session, as its shares rose above 8% on the day.
Aurinia Pharmaceuticals (AUPH) Shares March Higher, Can It Continue?
by Zacks Equity Research
Aurinia Pharmaceuticals Inc. (AUPH) has been on the move lately as the stock has risen by 41.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)?
by Zacks Equity Research
Investors certainly have to be happy with Aurinia Pharmaceuticals Inc. (AUPH) and its short term performance
Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%
by Zacks Equity Research
Aurinia Pharmaceuticals Inc. (AUPH) moved big last session, as its shares jumped almost 6% on the day.
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
by Zacks Equity Research
Investors in Aurinia Pharmaceuticals Inc. (AUPH) need to pay close attention to the stock based on moves in the options market lately.